A Phase 1, First in Human, Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ATB1651 in Adults With Mild to Moderate Onychomycosis
Latest Information Update: 13 Oct 2023
At a glance
- Drugs ATB 1651 (Primary)
- Indications Onychomycosis
- Focus Adverse reactions; First in man
- Sponsors AmtixBio
- 10 Oct 2023 Status changed from recruiting to completed.
- 27 Jul 2022 Number of treatment arms increased from 4 to 6.
- 27 Jul 2022 Status changed from not yet recruiting to recruiting.